Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Depreciation: 2019-2024

Historic Accumulated Depreciation for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $16.6 million.

  • 4D Molecular Therapeutics' Accumulated Depreciation rose 29.52% to $20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 29.52%. This contributed to the annual value of $16.6 million for FY2024, which is 39.00% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Accumulated Depreciation of $16.6 million as of FY2024, which was up 39.00% from $11.9 million recorded in FY2023.
  • 4D Molecular Therapeutics' Accumulated Depreciation's 5-year high stood at $16.6 million during FY2024, with a 5-year trough of $3.8 million in FY2020.
  • Over the past 3 years, 4D Molecular Therapeutics' median Accumulated Depreciation value was $11.9 million (recorded in 2023), while the average stood at $12.1 million.
  • Data for 4D Molecular Therapeutics' Accumulated Depreciation shows a peak YoY skyrocketed of 54.40% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Accumulated Depreciation stood at $3.8 million in 2020, then spiked by 38.53% to $5.3 million in 2021, then skyrocketed by 45.13% to $7.7 million in 2022, then skyrocketed by 54.40% to $11.9 million in 2023, then skyrocketed by 39.00% to $16.6 million in 2024.